Comparative Pharmacology
Head-to-head clinical analysis: ANDRODERM versus METANDREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDRODERM versus METANDREN.
ANDRODERM vs METANDREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.
Androgen receptor agonist; binds to androgen receptors in target tissues, activating gene transcription and promoting protein synthesis, growth of male reproductive organs, and secondary sexual characteristics.
Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.
Oral: 5-25 mg once daily for testosterone replacement therapy in adult males.
None Documented
None Documented
Terminal elimination half-life is approximately 10–100 minutes (rapid), but due to transdermal absorption, effective half-life is extended to about 8–10 hours after patch application.
The terminal elimination half-life of methyltestosterone is approximately 3-4 hours. This short half-life necessitates multiple daily dosing (e.g., 10-50 mg orally 1-3 times daily) to maintain therapeutic androgen levels. However, due to its oral administration and first-pass metabolism, the clinical effect may last longer.
Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates; 6% are excreted in feces via bile.
Metandren (methyltestosterone) is primarily metabolized in the liver and excreted in the urine as glucuronide and sulfate conjugates. Approximately 90% of a dose is excreted renally, with less than 5% eliminated via feces. Biliary excretion is minimal.
Category C
Category C
Androgen
Androgen